Advent receives US NIH grant for bronchopulmonary dysplasia therapy
Advent Therapeutics has received a grant worth $3m from the US NIH for expediting the development of bronchopulmonary dysplasia therapy.
Advent Therapeutics has received a grant worth $3m from the US NIH for expediting the development of bronchopulmonary dysplasia therapy.
What's Your Reaction?
